2021/12/08 - Financial public releases

United States: Virbac announces the FDA approval of a tulathromycin injectable and a collaboration with Pharmgate

Vignette_300X200_Porc_0000_P1033761.00_00_10_27.Still001.jpgVirbac's first steps into the U.S. food producing animal market.

On December 6, Virbac announced the launch of its first product in the U.S. food producing animal market with the FDA approval of Tulissin (tulathromycin injectable solution) for use in cattle and swine.

Virbac will market the cattle products with its own direct sales force; whereas for swine, Virbac announces that it has entered into an agreement with Pharmgate. Under this arrangement, Pharmgate, with a very robust sales and technical services division, will represent Virbac to swine veterinarians and producers across the U.S. 

Virbac has a very strong presence in the large animal health segment in several regions, including Asia, Pacific, Europe and Latin America. This will be Virbac’s first foray into this segment for the U.S. market.

“We are excited to collaborate with a reputable animal health organization, such as Virbac, as they launch a range of products into the U.S. large animal market,” says Ed Seed, head of Global Sales & Marketing for Pharmgate. “Adding this initial product, Tulissin, to our portfolio over the coming year will expand our offering in fulfilling our customers’ complete therapeutic product needs.” 

“We see the market authorization of Tulissin as a major accomplishment and are excited about our introduction into the food producing animal market for the U.S. I am convinced that Pharmgate, with its broad portfolio of products and strong field team, key relationships and expertise, is a perfect fit for Virbac to successfully enter the swine segment,” says Francois Fournier, president & CEO, Virbac North America.